目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T8408 | NADPH-oxidase NADPH | ||
GKT136901 (AK120765) 是选择性的和具有口服活性的 NADPH 氧化酶 NOX-1/4抑制剂,Ki 分别为 160 和 165 nM。它具有抗炎症活性。它也是一种选择性和直接的过氧亚硝酸清除剂。它可用于糖尿病肾病,中风和神经退行性疾病的研究。 | |||
T10353 | NADPH-oxidase NADPH | ||
APX-115 free base (Ewha-18278 free base) 是口服具有活性的、非选择性的 Nox 抑制剂,对 Nox1,Nox2和 Nox4的 Ki 分别为 1.08 μM,0.57 μM 和 0.63 μM。它能够有效预防糖尿病小鼠的肾损伤。 | |||
T81647 | |||
NOX2-IN-2(化合物33)作为一种高效的NOX2抑制剂,其作用机制是针对p47phox-p22phox的蛋白-蛋白相互作用,具有0.24 μM的Ki值。该化合物能够抑制NOX2在细胞内产生的ROS。 | |||
T81648 | |||
NOX2-IN-1 是 NOX2 (烟酰胺腺嘌呤二核苷酸磷酸氧化酶异构体 2) 的抑制剂。该化合物旨在针对 p47phox-p22phox 蛋白间相互作用,展现出优秀的结合亲和力及细胞活性。 | |||
T29097 | Apoptosis NADPH-oxidase | ||
VAS 3947 是一种特异的 NADPH 氧化酶 (NOX) 抑制剂。VAS 3947具有强大的抗血小板作用, 通过 UPR 激活,主要由于蛋白质聚集和错误折叠,独立于抗 NOX 活性诱导细胞凋亡。 | |||
T22096 | |||
L 012 sodium salt 是一种 luminol 类似物,是一种广泛使用的活性氧和活性氮的化学发光(CL)探针 的化学发光 (CL) 探针。L 012 sodium salt 广泛用于检测 NADPH 氧化酶 (Nox) 衍生的超氧化物 (O2•−) ,用于发现 Nox 抑制剂。 | |||
T3834 | ROS Immunology/Inflammation related | ||
8-Epideoxyloganic acid 是从 Incarvillea delavayi 中分离得到的一种环烯醚萜苷。它具有微弱的缓解疼痛活性。 | |||
T10354 | NADPH-oxidase | ||
APX-115 (Ewha-18278) (Ewha-18278) 是一种有效的,口服活性的,非选择性 Nox 抑制剂,对 Nox1,Nox2 和 Nox4 的 Ki 值分别为 1.08 μM,0.57 μM 和 0.63 μM。APX-115 可有效预防糖尿病小鼠的肾损伤。 | |||
T3S1416 | Apoptosis PKC | ||
Decursin (Decursinol angelate) 是一种细胞毒性剂,是一种来自朝鲜当归根的有效蛋白激酶 C 激活剂。它通过 Hippo/YAP 信号通路抑制 HepG2 细胞的生长。它通过下调 CXCR7 表达来抑制胃癌中的肿瘤生长,迁移和侵袭。 | |||
T79179 | |||
GLX481304是一种针对Nox-2和-4的特异性抑制剂,具有1.25 μM的半抑制浓度(IC50)。它能减少离体小鼠心肌细胞中活性氧(ROS)的生成,并增强心肌收缩功能。此化合物适用于心脏缺血性损伤研究。 |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-01276 | ENOX1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 24 minutes and play a role in control of the ultradian cellular biological clock.
|
|||||
TMPJ-00848 | NCF1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Neutrophil cytosol factor 1( NCF1) is a 47 kDa cytosolic subunit of neutrophil NADPH oxidase. This oxidase is characterized as a multicomponent enzyme which is activated to produce superoxide anion. NCF2, NCF1, and a membrane bound cytochrome b558 are required for the activation of the latent NADPH oxidase. The human NCF1 gene encodes a 390 amino acids protein without a signal peptide. The NCF1 gene interacts with other subunits of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) and plays an important role in innate immunity, producing reactive oxygen species and reducing the severity and duration of parasitic infection and autoimmune disease. NCF1 also has a role in T cell activation.
|
|||||
TMPH-01744 | NOX1 Protein, Human, Recombinant (His) | Human | E. coli | ||
NOH-1S is a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes and other tissues. It participates in the regulation of cellular pH and is blocked by zinc. NOH-1L is a pyridine nucleotide-dependent oxidoreductase that generates superoxide and might conduct H(+) ions as part of its electron transport mechanism, whereas NOH-1S does not contain an electron transport chain. NOX1 Protein, Human, Recombinant (His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 67.7 kDa and the accession number is Q9Y5S8.
|
|||||
TMPH-01278 | ENOX2 Protein, Human, Recombinant (His & Myc) | Human | E. coli | ||
May be involved in cell growth. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock.
|
|||||
TMPH-01277 | ENOX2 Protein, Human, Recombinant | Human | E. coli | ||
May be involved in cell growth. Probably acts as a terminal oxidase of plasma electron transport from cytosolic NAD(P)H via hydroquinones to acceptors at the cell surface. Hydroquinone oxidase activity alternates with a protein disulfide-thiol interchange/oxidoreductase activity which may control physical membrane displacements associated with vesicle budding or cell enlargement. The activities oscillate with a period length of 22 minutes and play a role in control of the ultradian cellular biological clock.
|
|||||
TMPH-01745 | NOX4 Protein, Human, Recombinant (Cell-Free, His) | Human | E. coli | ||
NOX4 Protein, Human, Recombinant (Cell-Free, His) is expressed in E. coli expression system with N-10xHis tag. The predicted molecular weight is 69.8?kDa and the accession number is Q9NPH5.
|
|||||
TMPH-01746 | NOX4 Protein, Human, Recombinant (E. coli, His) | Human | E. coli | ||
NOX4 Protein, Human, Recombinant (E. coli, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 28.8 kDa and the accession number is Q9NPH5.
|
|||||
TMPY-02391 | SUMO1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.
|